These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1436320)

  • 21. Erythropoietin use in a Jehovah's Witness patient.
    Walton T; Macon EJ
    Ann Pharmacother; 2002 Apr; 36(4):729-30. PubMed ID: 11936087
    [No Abstract]   [Full Text] [Related]  

  • 22. Erythropoietin: issues in its use as a therapeutic for the anemia of chronic renal failure.
    Eschbach JW; Adamson JW
    Blood Purif; 1990; 8(5):239-54. PubMed ID: 2091684
    [No Abstract]   [Full Text] [Related]  

  • 23. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
    Berns JS; Rudnick MR; Cohen RM
    Am J Kidney Dis; 1991 Jul; 18(1):143. PubMed ID: 2063850
    [No Abstract]   [Full Text] [Related]  

  • 24. Recombinant human erythropoietin (rHuEPO) in the treatment of anaemia of chronic renal failure.
    Desai JD; Shah BV
    J Assoc Physicians India; 1991 Jun; 39(6):483-5. PubMed ID: 1938855
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of renal anemia using synthetic human erythropoietin].
    Blumberg A; Zehnder C
    Ther Umsch; 1988 Dec; 45(12):895-9. PubMed ID: 3065970
    [No Abstract]   [Full Text] [Related]  

  • 26. Gain in recombinant human erythropoietin dosage with continuous intravenous intradialytic administration for the treatment of anaemia in end-stage renal disease.
    Liani M; Salvati F; Golato M; Cahen R
    Nephron; 1995; 69(2):189. PubMed ID: 7723913
    [No Abstract]   [Full Text] [Related]  

  • 27. The end stage renal disease program.
    Goodkin DA
    N Engl J Med; 1993 Jul; 329(2):140; author reply 140-1. PubMed ID: 8510703
    [No Abstract]   [Full Text] [Related]  

  • 28. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul; 317(4):249-51. PubMed ID: 3600716
    [No Abstract]   [Full Text] [Related]  

  • 29. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 30. Treating the anaemia of a pregnancy with heterozygous beta thalassaemia with recombinant human erythropoietin (r-HuEPO).
    Juncà J; Vela D; Orts M; Riutort N; Feliu E
    Eur J Haematol; 1995 Oct; 55(4):277-8. PubMed ID: 7589350
    [No Abstract]   [Full Text] [Related]  

  • 31. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis.
    Cotton SL; Holechek MJ
    ANNA J; 1989 Dec; 16(7):463-8. PubMed ID: 2604448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to recombinant human erythropoietin in a child with renal failure, cystinosis and beta-thalassaemia minor.
    Milford DV; Winterborn MH
    Nephron; 1993; 64(4):645-6. PubMed ID: 8366996
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of recombinant erythropoietin on electrolytes and nutrition in end-stage renal disease patients.
    Kaupke CJ; Vaziri ND
    Int J Artif Organs; 1993 Feb; 16(2):59-62. PubMed ID: 8486413
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythropoietin in renal anemia].
    Peña Amaro MP; García López J; Camacho Romera M
    Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.